Entera Bio Ltd
Entera Bio Ltd (ENTX) Covered Calls
Read more
Running ENTX covered calls helps you generate income from Entera Bio Ltd shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ENTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ENTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ENTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ENTX covered call is worth writing.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
No illustrative rows to display.
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank29.37% Low
- Market cap (M$)542
- 52 weeks high-25.95%
- 52 weeks low241.76%
- Analyst recommendationStrong Buy
1.00 - Target price$10.00
231.13% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-06
- P/E—
- Future P/E—
- EPS (ttm)-0.39
- EPS growth next 5 years-16.72%
As of Nov 13, 2026